Amphastar Pharmaceuticals Stock

Amphastar Pharmaceuticals ROE 2024

Amphastar Pharmaceuticals ROE

0.22

Ticker

AMPH

ISIN

US03209R1032

WKN

A11664

In 2024, Amphastar Pharmaceuticals's return on equity (ROE) was 0.22, a 24.43% increase from the 0.17 ROE in the previous year.

Amphastar Pharmaceuticals Aktienanalyse

What does Amphastar Pharmaceuticals do?

Amphastar Pharmaceuticals Inc is a leading biopharmaceutical company that focuses on the development, manufacturing, and marketing of generic and innovative drugs. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. History Amphastar Pharmaceuticals has a remarkable history in the generic industry. The company was founded by Dr. Jack Y. Zhang and Dr. Zhaocheng Guo, both of whom had doctorates in pharmacy. They initially worked as scientists at other pharmaceutical companies before deciding to start their own company. The beginning was difficult as they had limited financial resources and faced tough competition in the industry. However, the company grew through acquiring smaller competitors and developing its own products. Business Model Amphastar Pharmaceuticals' business model is based on the development, manufacturing, and marketing of generic drugs that meet medical needs. The company specializes in the treatment of diseases such as diabetes, heart disease, infections, and cancer. Utilizing unused patents and collaborations plays an important role in accessing new markets. Divisions Amphastar Pharmaceuticals is divided into three divisions: Human Pharmaceuticals, Veterinary Pharmaceuticals, and API (Active Pharmaceutical Ingredients). The Human Pharmaceuticals division specializes in developing products for the treatment of diseases such as diabetes, heart disease, infections, and cancer. The Veterinary Pharmaceuticals division focuses on developing veterinary drugs for livestock and pets. The API division is responsible for manufacturing raw materials for the pharmaceutical industry. Products Amphastar Pharmaceuticals offers a wide range of products, including inhalation aids for asthma, antidepressants, antidotes for anesthetics, anesthetics, drugs for cancer therapies, as well as for the treatment of HIV infections and nervous system disorders. In the field of veterinary products, Amphastar produces antibiotics, antifungals, vitamins, and hormones for animals. Conclusion Amphastar Pharmaceuticals Inc is a successful biopharmaceutical company specializing in the development, manufacturing, and marketing of generic and innovative drugs for a wide range of diseases. Since its inception, the company has been focused on growth and has continuously evolved through acquiring smaller competitors and developing its own products. The company offers a wide range of products for use in human and veterinary medicine and places special emphasis on providing high-quality drugs. Amphastar Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Amphastar Pharmaceuticals's Return on Equity (ROE)

Amphastar Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Amphastar Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Amphastar Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Amphastar Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Amphastar Pharmaceuticals stock

What is the ROE (Return on Equity) of Amphastar Pharmaceuticals this year?

The ROE of Amphastar Pharmaceuticals this year is 0.22 undefined.

How has the Return on Equity (ROE) of Amphastar Pharmaceuticals developed compared to the previous year?

The ROE of Amphastar Pharmaceuticals has increased by 24.43% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Amphastar Pharmaceuticals?

A high ROE indicates that Amphastar Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Amphastar Pharmaceuticals?

A low ROE can indicate that Amphastar Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Amphastar Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Amphastar Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Amphastar Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Amphastar Pharmaceuticals?

Some factors that can influence Amphastar Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Amphastar Pharmaceuticals pay?

Over the past 12 months, Amphastar Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amphastar Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Amphastar Pharmaceuticals?

The current dividend yield of Amphastar Pharmaceuticals is .

When does Amphastar Pharmaceuticals pay dividends?

Amphastar Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Amphastar Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amphastar Pharmaceuticals located?

Amphastar Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amphastar Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amphastar Pharmaceuticals from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Amphastar Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Amphastar Pharmaceuticals in the year 2023?

In the year 2023, Amphastar Pharmaceuticals distributed 0 USD as dividends.

In which currency does Amphastar Pharmaceuticals pay out the dividend?

The dividends of Amphastar Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Amphastar Pharmaceuticals

Our stock analysis for Amphastar Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amphastar Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.